

CLAIMS

1. (original) An oligonucleotide comprising at least 18 nucleotides, wherein the sequence is complementary to an mRNA encoding human integrin-linked kinase.

2. (original) The oligonucleotide according to Claim 1, wherein said sequence is complementary to SEQ ID NO:1.

3. (currently amended) The oligonucleotide according to Claim 2, wherein said sequence is selected from the group consisting of SEQ NO:43 3 to SEQ ID NO:109 99.

4. (original) The oligonucleotide according to Claim 3; and a pharmaceutically acceptable carrier.

5. (original) A method of inhibiting expression of integrin linked kinase, the method comprising:

administering an oligonucleotide composition comprising an oligonucleotide comprising at least 18 nucleotides, wherein the sequence is complementary to an mRNA encoding human integrin linked kinase; and a pharmaceutically acceptable carrier.

6. (original) The method according to Claim 5, wherein said sequence is complementary to SEQ ID NO:1.

7. (currently amended) The method according to Claim 6, wherein said sequence is selected from the group consisting of SEQ NO:43 3 to SEQ ID NO:109 99.